These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16224447)

  • 1. Recurrent ovarian cancer.
    Tummala MK; McGuire WP
    Clin Adv Hematol Oncol; 2005 Sep; 3(9):723-36. PubMed ID: 16224447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
    Eisenhauer EL; Sonoda Y; Levine DA; Abu-Rustum NR; Gemignani ML; Sabbatini PJ; Barakat RR; Chi DS
    Am J Obstet Gynecol; 2008 Feb; 198(2):213.e1-7. PubMed ID: 18226627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival following the documentation of platinum and taxane resistance in ovarian cancer.
    Büyükçelik A; Yalçin B; Utkan G; Doruk H
    Gynecol Oncol; 2004 Dec; 95(3):774-5; author reply 775-6. PubMed ID: 15582006
    [No Abstract]   [Full Text] [Related]  

  • 4. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 1997 Jun; 65(3):434-6. PubMed ID: 9190971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of chemotherapy in epithelial ovarian cancer.
    Markman M
    Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies: tailored treatment for ovarian cancer: are we there yet?
    Sessa C; Del Conte G
    Nat Rev Clin Oncol; 2010 Feb; 7(2):80-2. PubMed ID: 20118979
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Du XL; Parikh RC; Lairson DR; Giordano SH; Cen P
    Med Oncol; 2013 Mar; 30(1):440. PubMed ID: 23307252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing for starting second-line therapy in recurrent ovarian cancer.
    Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):49-55. PubMed ID: 21166510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
    Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
    Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary therapy for epithelial ovarian cancer--1994.
    Sutton GP
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):32-6. PubMed ID: 8091239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concerns with "maintenance chemotherapy" for patients with recurrent platinum-sensitive ovarian cancer.
    Markman M
    Gynecol Oncol; 1999 Jun; 73(3):469-70; author reply 470-2. PubMed ID: 10366485
    [No Abstract]   [Full Text] [Related]  

  • 16. Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy.
    Landoni F; Pellegrino A; Cormio G; Milani R; Maggioni A; Mangioni C
    Acta Obstet Gynecol Scand; 1998 Feb; 77(2):233-7. PubMed ID: 9512334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
    Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
    Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
    Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
    Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.